8.7
Excellent
376 reviews
- Communication
- 8.8
- Timeliness
- 8.9
- Accuracy
- 7.6
- Staff
- 8.8
- Value
- 8.9
Cameron Hand-Collier
5.4
- - Process Development
- - 14 weeks June - September 2024
- - Biotech Company
Reviewed:
Process development project faced delays, communication issues.
The process development project encountered multiple delays, and communication was inconsistent. We had to extend our project timeline due to the setbacks, and this impacted our overall production schedule. The team was capable but seemed overextended.
Rosemarie Labadie
5.6
- - Clinical Data Management
- - 8 weeks December 2023 - February 2024
- - Biotech Company
Reviewed:
Delayed delivery and lack of communication during the project.
The data management services were delayed, and communication from the team was lacking. It was difficult to get updates, and when the deliverables arrived, they were not as polished as expected. The delays impacted our project timeline significantly.
Miss Heidi Russel
8.9
- - Stability Studies
- - 18 months January 2023 - June 2024
- - Pharmaceutical Company
Reviewed:
Accurate and reliable stability studies, clear reporting.
The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.
Bryant Abernathy
8.7
- - Patient Recruitment
- - 8 weeks March - April 2023
- - Clinical Research Organization
Reviewed:
Highly effective patient recruitment strategies, project completed on time.
The patient recruitment strategies were highly effective, and the project was completed within the agreed timeframe. The team was very professional, and their expertise in patient engagement was evident throughout.
Carolyn Collier
8.8
- - Biostatistical Design
- - 4 weeks May - June 2023
- - Research Institution
Reviewed:
Excellent biostatistical support, clear and actionable insights.
The biostatistical support provided was top-notch, offering clear and actionable insights that were critical to the success of our study. The team was responsive and worked closely with us to ensure the analysis met our specific needs.
Kay Monahan
6.2
- - Clinical Protocol Design
- - 10 weeks January - March 2024
- - Pharmaceutical Company
Reviewed:
Inconsistent quality of deliverables, frequent revisions needed.
The protocol design process required multiple revisions due to inconsistencies in the deliverables. Although the team was responsive to feedback, the back-and-forth extended the timeline beyond what was originally agreed upon.
Jody Mertz PhD
9.3
- - Market Access Strategy
- - 6 weeks January - February 2024
- - Pharmaceutical Company
Reviewed:
Strategic market access analysis, insightful recommendations.
The market access analysis provided strategic insights that were crucial to our launch strategy. The team's recommendations were data-driven and actionable, helping us to make informed decisions.
Linda Ankunding
9.2
- - Data Analysis
- - 4 weeks January 2023
- - Pharmaceutical Company
Reviewed:
Thorough data analysis, timely delivery, excellent communication throughout.
The team provided exceptional data analysis services, and the project was completed well within the timeline. Communication was clear and consistent, which made the whole process smooth. Highly recommended for anyone needing reliable clinical data management.
